Journal des probiotiques et de la santé
Libre accès

Abstrait

Study of Interferonogenous Activity of the New Probiotic Formulation Del-Immune V^®

Liubov Sichel, Natalya A Timoshok, Valentyn S Pidgorskyy and Nykolay Y Spivak

Abstract
Background: Mechanisms of action and optimal doses have not yet been determined for the immunomodulator Del-Immune V®, a supplement containing dry fermental cell lysate and DNA fragments of the probiotic strain Lactobacillus rhamnosus V (DV Strain).
Objective: To study the mechanisms of Del-Immune V® immunomodulation and to investigate dose-dependent effects on immunoregulatory cytokines production in vivo and in vitro.
Design: One hundred forty inbred laboratory mice with body masses ranging from 14-16 grams were divided into 7 test groups. Groups I, II, and III received 0.5 ml of aqueous solution of Del-Immune V® by mouth in doses of 5, 50, and 500 μg per mouse, respectively, for 5 days at 24-hour intervals. Group IV mice received 0.5 ml Bifi dim suspension by mouth in a dose of 50 μg/mouse on the same schedule. Group V mice (control group) received 0.15 M NaCl. Group VI and VII mice received a single dose of 50 μg/mouse Del-Immune V® (Group VI) or Bifi dim (Group VII) on day 1 of the test period. Eight hours after administration and every 24 hours thereafter for 5 days, blood serum, peritoneal exudate macrophages, and splenocytes were obtained from each group for testing. Interferonogenous activity of cultured splenocytes and serum levels of interferon were assessed.
Results: Groups I-IV showed a marked increase of IFN levels in blood serum after administration of Del-Immune V® or Bifi dim; the optimal daily dose was found to be 50 μg/mouse. The highest serum IFN level was reported 24 hours after administration. The control group remained unchanged. Maintenance of elevated circulating IFN was possible only through repeated administration.
Conclusions: In this study, a 50 μg/mouse dose of Del-Immune V® was shown to actively induce IFN and moderately stimulate the production of TNF, showing signifi cant promise as an immunomodulating preparation.